Pages that link to "Q425154"
Jump to navigation
Jump to search
The following pages link to tocilizumab (Q425154):
Displaying 50 items.
- arthritis (Q170990) (← links)
- Takayasu's arteritis (Q432462) (← links)
- giant cell arteritis (Q707816) (← links)
- adult-onset Still's disease (Q1187697) (← links)
- polyarthritis (Q1274464) (← links)
- polymyalgia rheumatica (Q1752891) (← links)
- Castleman's disease (Q1947302) (← links)
- systemic-onset juvenile idiopathic arthritis (Q17148432) (← links)
- Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab (Q21146701) (← links)
- Tocilizumab for rheumatoid arthritis (Q24234126) (← links)
- Tocilizumab for rheumatoid arthritis (Q24239949) (← links)
- Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab (Q24598109) (← links)
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study (Q24630541) (← links)
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) (Q24631295) (← links)
- Tocilizumab (Q24655317) (← links)
- Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm (Q26801742) (← links)
- Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? (Q26824294) (← links)
- Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors (Q26824970) (← links)
- Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab (Q27023091) (← links)
- Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review (Q27024465) (← links)
- Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis (Q28071389) (← links)
- Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis (Q28073706) (← links)
- Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab (Q28080677) (← links)
- Tocilizumab: a review of its use in the management of rheumatoid arthritis (Q28241360) (← links)
- Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses (Q28289228) (← links)
- (Q28295371) (← links)
- Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease (Q28304633) (← links)
- Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study) (Q28551709) (← links)
- Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis (Q28943301) (← links)
- Roactemra (Q29006460) (← links)
- Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. (Q30235357) (← links)
- Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data (Q30612998) (← links)
- Identifying newly approved medications in Medicare claims data: a case study using tocilizumab (Q30667044) (← links)
- Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data (Q30769719) (← links)
- Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study (Q30882161) (← links)
- The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials (Q30914777) (← links)
- Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt (Q30956564) (← links)
- Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data (Q31110789) (← links)
- Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab (Q31123794) (← links)
- Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System (Q31133235) (← links)
- Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources (Q31137082) (← links)
- Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials (Q31151183) (← links)
- Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. (Q31156243) (← links)
- Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab (Q33388583) (← links)
- Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis (Q33390797) (← links)
- Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. (Q33400338) (← links)
- Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor (Q33400381) (← links)
- Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody (Q33401448) (← links)
- Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody (Q33408768) (← links)
- Tocilizumab in severe and refractory non-infectious uveitis. (Q33417913) (← links)